Opportunity ID: 55504

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-AI-10-009
Funding Opportunity Title: Martin Delaney Collaboratory: Towards an HIV-1 Cure (U19)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.242 — Mental Health Research Grants
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Jun 28, 2010
Last Updated Date:
Original Closing Date for Applications: Nov 04, 2010
Current Closing Date for Applications: Nov 04, 2010
Archive Date: Dec 05, 2010
Estimated Total Program Funding: $8,500,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: County governments
Special district governments
Native American tribal organizations (other than Federally recognized tribal governments)
Native American tribal governments (Federally recognized)
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Public housing authorities/Indian housing authorities
State governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Independent school districts
Others (see text field entitled “Additional Information on Eligibility” for clarification)
City or township governments
For profit organizations other than small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: Purpose. The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH), National Institutes of Health (NIH), encourage grant applications from institutions/organizations to address the problem of HIV-1 persistence in HIV-1-infected persons treated with suppressive antiretroviral drug regimens. This FOA will support research in four areas: (1) basic research to identify and characterize the cellular reservoirs of HIV-1 in treated individuals, (2) development of assays that are physiologically relevant and that comprise a spectrum of cell types that may harbor latent HIV-1 or permit viral replication in the presence of effective antiretroviral drug regimens, (3) screening of drug candidates that target latent/persistent HIV-1, and (4) development and initial testing of new agents or strategies aimed at the eradication of HIV-1. The goal of this initiative is to expand the knowledge base on HIV-1 latency and persistence so that eradication strategies can be designed, developed and evaluated. The application must include basic research and translational activities as essential components, and collaborators must include a private sector entity.
Mechanism of Support. This FOA will utilize the U19 award mechanism.
Funds Available and Anticipated Number of Awards. For this funding opportunity, the total amount of funds available from NIAID and NIMH is $8.5M for fiscal year 2011. NIAID and NIMH expect to fund 1-2 awards.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-10-009.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

2025-07-11T16:41:19-05:00

Share This Post, Choose Your Platform!

About the Author: